Anti-CD24 antibody-nitric oxide donor conjugates bearing a self-bioorthogonal cleavable linker.

ABSTRACT: Triple-negative breast cancer (TNBC) is a highly aggressive malignancy predominantly managed via chemotherapy. Our clinical sample analysis revealed a significant correlation between elevated CD24 expression in TNBC tumor cells and patient survival rates. We developed a novel antibody-drug conjugate (ADC), named HN03, consisting of an antibody with engineered cysteines for site-specific conjugation with a low toxic nitric oxide (NO) precursor as its payload through a novel Pt(IV)-mediated bioorthogonal self-cleavable linker. HN03 specifically targets tumor cells expressing high levels of CD24, concurrently generating cisplatin and releasing NO upon activation. HN03 also exhibited potent in vitro and in vivo antitumor activity. It significantly redu

SUBMITTER: Wu J 

PROVIDER: S-EPMC12541613 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature